SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing intense discussion following a steep price drop triggered by a Raymond James downgrade related to its SCAR program recompetition, sparking community shock and claims of manipulation, though some view it as an overreaction given persistent defense sector demand.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending as escalating Middle East tensions, including retaliatory strikes on energy infrastructure and a major Saudi refinery shutdown, ignite a surge in global oil prices. The community is actively discussing the potential for a prolonged conflict to drive significant upside for INDO, drawing comparisons to past commodity-driven rallies in low-float energy stocks.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid a surging optical interconnect sector, driven by NVIDIA's intensified focus on photonics and strong community anticipation for breakthrough announcements. Investors and traders are actively discussing the company's wafer-scale technology as a pivotal solution for AI data center bottlenecks, further fueled by recent institutional endorsements and hints of significant customer engagements.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as the market defies initial bearish expectations following weekend geopolitical developments, with many observing a powerful short squeeze and a "buy the dip" mentality. The community is actively debating whether "war is bullish" or if the market is manipulated, highlighting disbelief at its resilience despite mounting global tensions.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending due to its recent acquisition of BrewDog assets for GBP 33M, a move dividing the community as some hail it as a strategic beverage diversification at a bargain, while others criticize investing in a struggling beer business. This comes as the broader cannabis sector anticipates potential U.S. rescheduling to Schedule III, prompting further debate over Tilray's core strategy as a Canadian LP.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is experiencing a surge in attention, driven by its highly active 'Rage Bros' community aggressively accumulating and expressing strong conviction. They frequently cite the project's status as an 'OG MEME' on Solana with deep cultural roots and continuous building, believing in its inevitable path to significant valuations.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid heightened geopolitical tensions, which are spotlighting the defense drone sector and fueling community discussions around the company's potential for significant military contracts for its Black Widow and FANG platforms. Investors are closely watching its participation in the Drone Dominance Program and upcoming Innovation Day for further clarity on future revenue and growth.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is actively discussed following its recent $1.17 billion equity offering, priced at $84 per share, which the community views as both a funding mechanism for accelerated drone and hypersonic production and a potential buying opportunity amidst increased global defense spending. As a leader in unmanned and attritable systems, the company's recent contract wins and inclusion in the Drone Dominance Program are bolstering bullish sentiment, reflecting its pivotal role in the evolving landscape of modern warfare.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is soaring amid a broad surge in the low-float oil and gas sector, driven by escalating Middle East tensions impacting crude prices. The community is heavily discussing its impressive momentum and potential for further short-squeeze action, while acknowledging the inherent volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market appears to be shrugging off heightened geopolitical tensions in the Middle East, with many in the community asserting that 'war is bullish' and advocating to 'buy the dip.' This unexpected resilience is leading to discussions about market manipulation and the crushing of bearish bets, particularly in tech-heavy names.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Merck & Co., Inc. $MRK Position Lifted by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC raised its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 25.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 217,170...

Elo Mutual Pension Insurance Co Has $24.19 Million Stake in Merck & Co., Inc. $MRK

Elo Mutual Pension Insurance Co raised its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 14.2% during the 3rd quarter, according to the company in its most recent 13F filing...

Fisher Asset Management LLC Sells 945,571 Shares of Merck & Co., Inc. $MRK

Fisher Asset Management LLC decreased its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 3.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange...

Davis R M Inc. Lowers Stake in Merck & Co., Inc. $MRK

Davis R M Inc. lessened its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 32.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The...

Bahl & Gaynor Inc. Sells 1,406,091 Shares of Merck & Co., Inc. $MRK

Bahl & Gaynor Inc. lowered its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 57.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange...

<ul class="summary-bullets"><li>The company's 2025 outlook shows EBIT loss narrowing to $256.03 million from $344.18 million a year ago.</li><li>Anktiva commercialization is driving traction, with 2025 net product revenue reaching $113 million, up 700% from the previous year.</li><li>ImmunityBio's Phase 2 Quilt 2.005 data shows higher cancer-free rates and a potential BLA filing expected by Q4.</li></ul>Shares of ImmunityBio, Inc. (IBRX) jumped 1% in overnight trading Sunday as investors positioned ahead of Tuesday’s earnings, with fresh weekend buzz around Anktiva following founder Patrick Soon-Shiong’s media appearances.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> jumped over 2% on Friday to $0.78 and added another 5% in after-hours trading.&nbsp;<h2 class="st-heading-2">Earnings Expectations Take Center Stage</h2>ImmunityBio is set to report its full-year 2025 earnings on Tuesday, with expectations building that losses may narrow as the company scales commercialization of Anktiva, its lead immunotherapy.Fiscal AI estimates for 2025 show an improvement across all metrics. Revenue is projected to rise to $113.29 million from $14.75 million in 2024, while earnings before interest and taxes (EBIT)&nbsp;are expected to narrow to a loss of $256.03 million from $344.18 million a year ago. Loss per share is forecast to improve to $0.38 from $0.59 in 2024.The company has already indicated strong commercial traction&nbsp;for Anktiva, recording $113 million in net product revenue for the drug in 2025, up 700% from the prior year, while fourth-quarter (Q4) revenue rose 431% to $38.3 million, topping Wall Street estimates of $37.8 million.Despite higher research spending pushing Q4 net loss to $61.9 million from $59.2 million, full-year net loss attributable to common shareholders improved to $351.4 million from a loss of $413.6 million in 2024.<h2 class="st-heading-2">Founder Highlights Anktiva On National TV</h2>Over the weekend, founder and executive chairman Patrick Soon-Shiong amplified the scientific importance of Anktiva through a series of national&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-retail-frenzy-founder-prime-time-tv-blitz-retail-saudi-funding-trump-tailwinds/cZTc3BORIRN">media appearances</a>, including an interview with Fox News Chief Political Anchor Bret Baier and participation in a live discussion with Christopher Cuomo on NewsNation.Reflecting on conversations aired during a segment focused on cancer research and treatment, Soon-Shiong highlighted&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2028173238338204093">on X</a> the importance of IL-15, the biological foundation of Anktiva, noting its ability to stimulate T cells, NK cells and memory T cells, which supports durable immune responses across multiple tumor types.Soon-Shiong also pointed to remarks from U.S. Food and Drug Administration (FDA) authorities that a validated mechanism of action can support additional indications, and highlighted the agency’s “plausible mechanism of action” pathway as a means to accelerate access to therapies such as IL-15. He added that results from the company’s Quilt trials in lung, breast, and pancreatic cancers showed that IL-15 has the potential to generate long-term immune memory.The founder also drew attention to combination approaches involving Anktiva and Merck’s Keytruda. He said checkpoint inhibitors such as Merck’s Keytruda work by removing the “brakes” on immune cells, while Anktiva helps grow and strengthen those immune cells. He said the combination could help patients respond if their cancer stops reacting to earlier immunotherapy.<h2 class="st-heading-2">Trial Progress Adds Momentum</h2>ImmunityBio recently completed enrollment ahead of schedule in its Phase 2 Quilt 2.005 trial evaluating Anktiva combined with BCG in patients with early-stage bladder cancer who had not previously received standard BCG therapy.The study enrolled 366 patients and an early FDA-requested review indicated improved outcomes with the combination. After six months, 85% of patients receiving Anktiva with BCG remained cancer-free compared with 57% treated with BCG alone. At nine months, 84% of patients on the combination showed no recurrence, compared with 52% on standard therapy.The company expects to submit a biologics license application for the regimen by the fourth quarter of 2026. Anktiva is already approved in combination with BCG for bladder cancer in the U.S. and has also received authorizations in the UK, Europe and Saudi Arabia. Saudi regulators recently granted accelerated approval for the therapy in combination with a checkpoint inhibitor in metastatic non-small cell lung cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX shifted from ‘extremely bullish’ to ‘bullish’ amid a 65% decline in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_3d2d4b49a6.webp" alt="ibrx ss.png" width="975" height="143"><figcaption>IBRX sentiment and message volume as of March 2 | Source: Stocktwits</figcaption></figure>One user noted that Keytruda currently generates more than $30 billion in annual sales and is set to face patent expiration in 2028, describing Anktiva as a “better” product that could benefit from that shift. They urged traders to “buy and hold” the stock.<stembedurl>https://stocktwits.com/Johann1011/message/646276968</stembedurl>Another user said, “I look forward to tomorrow's trading day. Things look promising for IBRX!!”<stembedurl>https://stocktwits.com/BullriderNkg/message/646274508</stembedurl>IBRX stock has skyrocketed nearly 400% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Patrick Soon-Shiong announces newest initiatives for Cancer MoonShot 2020 at Hyatt Regency Boston on October 26, 2016. (Photo by Darren McCollester/Getty Images for NantHealth, Inc.)

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend

Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda.

Equity

River Wealth Advisors LLC Boosts Stock Position in Merck & Co., Inc. $MRK

River Wealth Advisors LLC grew its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 24.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and...

Merck & Co., Inc. $MRK Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.3% during the third quarter, according to the company in its most recent disclosure with...

Quantbot Technologies LP Increases Stock Position in Merck & Co., Inc. $MRK

Quantbot Technologies LP boosted its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 125.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRK News

MRKMerck & Co Inc